Artificial Intelligence-Empowered Multistep Integrated Radiation Therapy Workflow for Nasopharyngeal Carcinoma.
Authors
Affiliations (6)
Affiliations (6)
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
- Shanghai United Imaging Healthcare Co., Ltd., Shanghai, China.
- Shenzhen United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China. Electronic address: [email protected].
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China. Electronic address: [email protected].
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China. Electronic address: [email protected].
Abstract
To establish an artificial intelligence (AI)-empowered multistep integrated (MSI) radiation therapy (RT) workflow for patients with nasopharyngeal carcinoma (NPC) and evaluate its feasibility and clinical performance. Patients with NPC scheduled for MSI RT workflow were prospectively enrolled. This workflow integrates RT procedures from computed tomography (CT) scan to beam delivery, all performed with the patient on the treatment couch. Workflow performance, tumor response, patient-reported acute toxicities, and quality of life were evaluated. From March 2022 to October 2023, 120 newly diagnosed, nonmetastatic patients with NPC were enrolled. Of these, 117 completed the workflow with a median duration of 23.2 minutes (range, 16.3-45.8). Median translation errors were 0.2 mm (from CT scan to planning approval) and 0.1 mm (during beam delivery). AI-generated contours required minimal revision for the high-risk clinical target volume and organs at risk, minor revision for the involved cervical lymph nodes and low-risk clinical target volume (median Dice similarity coefficients (DSC), 0.98 and 0.94), and more revision for the gross tumor at the primary site and the involved retropharyngeal lymph nodes (median DSC, 0.84). Of 117 AI-generated plans, 108 (92.3%) passed after the first optimization, with ≥97.8% of target volumes receiving ≥100% of the prescribed dose. Dosimetric constraints were met for most organs at risk, except the thyroid and submandibular glands. One hundred and fifteen patients achieved a complete response at week 12 post-RT, while 14 patients reported any acute toxicity as "very severe" from the start of RT to week 12 post-RT. AI-empowered MSI RT workflow for patients with NPC is clinically feasible in a single institutional setting compared with standard, human-based RT workflow.